CDK9 and hepatocellular carcinoma: As expected, pharmacological inhibition of CDK9 using 100 nM NVP-2 led to a decrease in Ser2 phosphorylation in a murine MYC;sgp53 HCC line, validating that it has on-target activity in our model (SI Appendix, Fig. S4B).